gpt-dict.com

Echinacea for Common Cold

Verdict: Weak, inconsistent evidence for colds

Echinacea is not a proven cold remedy: the strongest evidence shows no reliable benefit for treating colds and only a weak, clinically uncertain effect on prevention. Any modest benefit appears limited to specific preparations taken at the first sign of illness, not to echinacea products in general.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Weak (C) grade because the evidence is real but small, inconsistent, and clinically uncertain. The highest-quality and most independent source, the 2014 Cochrane review (24 double-blind trials, 4,631 people; PMID 24554461), found no demonstrated treatment benefit and only a weak preventive signal (a post hoc 10-20% relative risk reduction that was not significant in individual trials).

More optimistic reviews exist but are weaker. A 2007 meta-analysis (PMID 17597571) reported a 58% drop in cold odds (OR 0.42) and ~1.4 fewer sick days, yet later, more rigorous work did not replicate that magnitude. The most positive recent review, ERA-PRIMA 2024 (PMID 38667040, RR 0.68), has manufacturer-affiliated authors, and a 2025 pediatric meta-analysis (PMID 40311928) paired a modest benefit with more adverse events (RR 1.38). The core problem is huge product heterogeneity: species, plant part, and extraction differ enormously, so results do not generalize.

Regulators and clinics do not endorse it on trial evidence. The FDA treats products marketed as cold or COVID cures as unapproved drugs, while UK and WHO recognition is traditional-use only. Cleveland Clinic is openly negative, Mayo Clinic calls any effect modest at best, and Harvard is neutral. Echinacea is an immunostimulant contraindicated in autoimmune disease and Asteraceae (ragweed) allergy, so it should be used cautiously and only short-term.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.38
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.442
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Echinacea for preventing and treating the common cold
PMID: 24554461 2014 Cochrane SR n = 4,631
Finding: Across 24 double-blind trials (33 comparisons), none of the 12 prevention comparisons found a statistically significant reduction in cold incidence; a post hoc pooling implied a relative risk reduction of only 10-20% of unclear clinical relevance. For treatment, only one of seven duration trials showed significant superiority over placebo. The authors concluded Echinacea products have not been shown to provide benefits for treating colds, and any preventive effect is weak.
🟢 High quality Academic Effect size: Prevention: post hoc RRR 10-20% (not significant in individual comparisons); Treatment: 6 of 7 duration trials non-significant
View on PubMed
Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis
PMID: 17597571 2007 統合分析
Finding: Pooling 14 studies, echinacea decreased the odds of developing the common cold by 58% (OR 0.42, 95% CI 0.25-0.71) and shortened cold duration by about 1.4 days (WMD -1.44 days, 95% CI -2.24 to -0.64). Results remained significant across subgroup analyses.
Effect size: OR 0.42 (95% CI 0.25-0.71) for incidence; WMD -1.44 days (95% CI -2.24 to -0.64) for duration
View on PubMed
Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA)
PMID: 38667040 2024 統合分析 n = 5,652
Finding: Echinacea significantly reduced monthly RTI occurrence (RR 0.68, 95% CI 0.61-0.77) and the number of patients with at least one RTI (RR 0.75, 95% CI 0.69-0.81). It also reduced recurrent infections (RR 0.60, 95% CI 0.46-0.80), RTI complications (RR 0.44, 95% CI 0.36-0.54) and the need for antibiotic therapy (RR 0.60, 95% CI 0.39-0.93). Note: industry involvement (manufacturer-affiliated authors) reduces independence of this review.
🟠 Limited quality ⚠️ Industry-funded Effect size: RR 0.68 (95% CI 0.61-0.77) monthly RTI; RR 0.75 (95% CI 0.69-0.81) for >=1 RTI
View on PubMed
Efficacy and safety of Echinacea purpurea in treating upper respiratory infections and complications of otitis media in children: Systematic review and meta-analysis
PMID: 40311928 2025 統合分析 n = 3,169
Finding: In children, E. purpurea reduced URTI treatment duration (SMD -0.19, 95% CI -0.30 to -0.09), URTI incidence (RR 0.81, 95% CI 0.75-0.87) and antibiotic use (RR 0.18, 95% CI 0.13-0.25), and reduced otitis media episode incidence (RR 0.56, 95% CI 0.44-0.73). Adverse events were modestly increased (RR 1.38, 95% CI 1.08-1.78) but generally mild; the authors note the safety profile remains unclear.
Effect size: RR 0.81 (95% CI 0.75-0.87) URTI incidence; SMD -0.19 duration; RR 1.38 adverse events
View on PubMed
Echinacea in the prevention of induced rhinovirus colds: a meta-analysis
PMID: 16678640 2006 統合分析
Finding: Pooling experimental rhinovirus challenge studies, the likelihood of experiencing a clinical cold was 55% higher with placebo than with Echinacea (OR 1.55, 95% CI 1.02-2.36, p<0.043). No significant difference was found in symptom severity scores. The authors called for additional prospective studies.
🟠 Limited quality Effect size: OR 1.55 (95% CI 1.02-2.36) favouring Echinacea for prevention; severity NS
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
These products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act source↗
L4b EU EFSA
Neutral
L4c UK NHS
Neutral
Traditional herbal medicinal product used to relieve the symptoms of the common cold and influenza type infections, based on traditional use only. source↗
L4d TW TFDA / 衛福部
Neutral
每日食用限量為九百毫克。二歲以下之幼童、糖尿病患者、患有免疫相關疾病者或正在使用免疫相關藥物治療者，在使用前須先諮詢醫療人員。 source↗
L4e WHO
Neutral
WHO Monographs on Selected Medicinal Plants includes monographs on Herba Echinaceae Purpureae and Radix Echinaceae, covering quality control and the traditional and clinical uses of these medicinal plant materials. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Taking echinacea before you get sick may have a modest effect in preventing colds. Some studies show that this supplement doesn't work as a cold treatment, while others show some reduction in the severity and duration of cold symptoms when taken in the early stages of a cold. source↗
L5c Cleveland Clinic
Against
L5d Harvard Health
Neutral
L5e Specialty Society (condition-mapped)
Cautious
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-common-cold-INT-echinacea-001 繁體中文版 →